• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

IL-1R blockade is not effective in patients with hematological malignancies and severe SARS-CoV-2 infection.

作者信息

Villegas Carolina, Poza María, Talayero Paloma, Teller José Manuel Caro, Zafra Denis, Garcia Cristina, Vera Elena, Hidalgo Marta, Lopez Nieves, Cuellar Clara, Zamanillo Irene, Íñiguez Rodrigo, Paz-Artal Estela, Aguado José M, Martinez-Lopez J

机构信息

Hematology Department Hospital 12 de Octubre, i+12, Universidad Complutense, CNIO, CIBERONC, Madrid, Spain.

Immunology Department, Hospital Universitario "12 de Octubre," Instituto de Investigación Sanitaria Hospital "12 de Octubre" (imas12), Universidad Complutense, Madrid, Spain.

出版信息

Ann Hematol. 2020 Dec;99(12):2953-2956. doi: 10.1007/s00277-020-04160-w. Epub 2020 Jun 25.

DOI:10.1007/s00277-020-04160-w
PMID:32583087
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7314614/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/554e/7314614/e3c4755947e1/277_2020_4160_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/554e/7314614/e3c4755947e1/277_2020_4160_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/554e/7314614/e3c4755947e1/277_2020_4160_Fig1_HTML.jpg

相似文献

1
IL-1R blockade is not effective in patients with hematological malignancies and severe SARS-CoV-2 infection.白细胞介素-1受体阻断剂对血液系统恶性肿瘤和严重新型冠状病毒2感染患者无效。
Ann Hematol. 2020 Dec;99(12):2953-2956. doi: 10.1007/s00277-020-04160-w. Epub 2020 Jun 25.
2
Perspectives on anti-IL-1 inhibitors as potential therapeutic interventions for severe COVID-19.抗白细胞介素-1抑制剂作为重症COVID-19潜在治疗干预措施的前景。
Cytokine. 2021 Jul;143:155544. doi: 10.1016/j.cyto.2021.155544. Epub 2021 Apr 17.
3
Seroconversion and kinetic of anti SARS-COV-2 antibodies in 25 patients with hematological malignancies who recovered from SARS-COV-2 infection.25例从新型冠状病毒肺炎感染中康复的血液系统恶性肿瘤患者的血清转化及抗新型冠状病毒2抗体动力学
Hematol Oncol. 2021 Aug;39(3):428-431. doi: 10.1002/hon.2872. Epub 2021 May 5.
4
SARS-CoV-2 multisystem inflammatory syndrome in an adult presenting with polyarthritis treated with anakinra.一名成年患者出现多关节炎，经阿那白滞素治疗的新型冠状病毒2型多系统炎症综合征。
Rheumatology (Oxford). 2022 Feb 2;61(2):e33-e34. doi: 10.1093/rheumatology/keab697.
5
Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe COVID-19: A case report.白细胞介素-1 受体拮抗剂阿那白滞素联合瑞德西韦治疗重症 COVID-19：一例报告。
Int J Infect Dis. 2020 Aug;97:215-218. doi: 10.1016/j.ijid.2020.05.050. Epub 2020 May 16.
6
Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study.阿那白滞素联合甲泼尼龙治疗重症 COVID-19 肺炎和炎症过度激活患者：一项观察性队列研究。
J Allergy Clin Immunol. 2021 Feb;147(2):561-566.e4. doi: 10.1016/j.jaci.2020.11.006. Epub 2020 Nov 19.
7
Efficacy but side effects of anakinra therapy for chronic refractory gout in a renal transplant recipient with preterminal chronic renal failure.阿那白滞素治疗终末期慢性肾衰竭肾移植受者慢性难治性痛风的疗效及副作用
Joint Bone Spine. 2012 Dec;79(6):631. doi: 10.1016/j.jbspin.2012.04.009. Epub 2012 Jul 26.
8
Interleukin-1RA Mitigates SARS-CoV-2-Induced Inflammatory Lung Vascular Leakage and Mortality in Humanized K18-hACE-2 Mice.白细胞介素-1RA 减轻人源化 K18-hACE-2 小鼠中 SARS-CoV-2 诱导的炎症性肺血管渗漏和死亡率。
Arterioscler Thromb Vasc Biol. 2021 Nov;41(11):2773-2785. doi: 10.1161/ATVBAHA.121.316925. Epub 2021 Sep 9.
9
Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series.在中重度新型冠状病毒肺炎中使用阿那白滞素靶向炎症级联反应：病例系列
Ann Rheum Dis. 2020 Oct;79(10):1381-1382. doi: 10.1136/annrheumdis-2020-217706. Epub 2020 May 6.
10
Continuous positive airway pressure in COVID-19 patients with moderate-to-severe respiratory failure.COVID-19 合并中重度呼吸衰竭患者的持续气道正压通气。
Eur Respir J. 2021 Feb 17;57(2). doi: 10.1183/13993003.02524-2020. Print 2021 Feb.

引用本文的文献

1
Current evidence on the use of anakinra in COVID-19.目前关于阿那白滞素在 COVID-19 中的应用的证据。
Int Immunopharmacol. 2022 Oct;111:109075. doi: 10.1016/j.intimp.2022.109075. Epub 2022 Jul 20.
2
Single Dose of Ivermectin is not Useful in Patients with Hematological Disorders and COVID-19 Illness: A Phase II B Open Labelled Randomized Controlled Trial.单剂量伊维菌素对血液系统疾病合并新冠病毒疾病患者无效：一项II B期开放标签随机对照试验
Indian J Hematol Blood Transfus. 2022 Oct;38(4):615-622. doi: 10.1007/s12288-022-01546-w. Epub 2022 May 27.
3
COVID-19 in Patients with Hematologic Malignancies: Clinical Manifestations, Persistence, and Immune Response.

本文引用的文献

1
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study.在患有新冠肺炎、急性呼吸窘迫综合征和炎症反应过度的患者中使用高剂量阿那白滞素进行白细胞介素-1阻断：一项回顾性队列研究。
Lancet Rheumatol. 2020 Jun;2(6):e325-e331. doi: 10.1016/S2665-9913(20)30127-2. Epub 2020 May 7.
2
Immunotherapies for COVID-19: lessons learned from sepsis.新冠病毒病的免疫疗法：脓毒症的经验教训
Lancet Respir Med. 2020 Oct;8(10):946-949. doi: 10.1016/S2213-2600(20)30217-4. Epub 2020 Apr 28.
3
Effective treatment of severe COVID-19 patients with tocilizumab.
COVID-19 与血液系统恶性肿瘤患者：临床表现、持续性和免疫反应。
Acta Haematol. 2022;145(3):297-309. doi: 10.1159/000523872. Epub 2022 Mar 2.
4
Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study.阿那白滞素治疗托珠单抗治疗抵抗的重症 COVID-19 的疗效：一项单中心回顾性对照研究。
Int J Infect Dis. 2021 Apr;105:319-325. doi: 10.1016/j.ijid.2021.02.041. Epub 2021 Feb 13.
托珠单抗治疗重症 COVID-19 患者有效。
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975. doi: 10.1073/pnas.2005615117. Epub 2020 Apr 29.
4
Cytokine release syndrome in severe COVID-19.重症新型冠状病毒肺炎中的细胞因子释放综合征
Science. 2020 May 1;368(6490):473-474. doi: 10.1126/science.abb8925. Epub 2020 Apr 17.
5
Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.基于对来自中国武汉的150名患者数据的分析得出的COVID-19相关死亡的临床预测因素。
Intensive Care Med. 2020 May;46(5):846-848. doi: 10.1007/s00134-020-05991-x. Epub 2020 Mar 3.
6
Overview of the IL-1 family in innate inflammation and acquired immunity.IL-1 家族在天然免疫和获得性免疫中的概述。
Immunol Rev. 2018 Jan;281(1):8-27. doi: 10.1111/imr.12621.
7
Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial.白细胞介素-1受体阻断与具有巨噬细胞活化综合征特征的脓毒症患者死亡率降低相关：对一项既往III期试验的重新分析
Crit Care Med. 2016 Feb;44(2):275-81. doi: 10.1097/CCM.0000000000001402.
8
Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies.巨噬细胞活化综合征的发病机制及细胞因子导向治疗的潜力。
Annu Rev Med. 2015;66:145-59. doi: 10.1146/annurev-med-061813-012806. Epub 2014 Nov 5.